A new combination of immunotherapy and chemotherapy for pancreatic cancer caused tumours to shrink in the majority of evaluable patients - 20 out of 24 as of an interim analysis of the phase 1b trial data. The early findings provide hope that this...
Original Article: AACR 2019: CD40 combination therapy can shrink pancreatic tumours